Triple
T22797003
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | AveXis |
E564274
|
entity |
| Predicate | changedNameTo |
P3432
|
FINISHED |
| Object | Novartis Gene Therapies |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Novartis Gene Therapies | Statement: [AveXis, changedNameTo, Novartis Gene Therapies]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Novartis Gene Therapies Context triple: [AveXis, changedNameTo, Novartis Gene Therapies]
-
A.
CRISPR Therapeutics
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat serious diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
D.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Novartis Gene Therapies Target entity description: Novartis Gene Therapies is a biotechnology company within Novartis focused on developing and commercializing gene therapy treatments for rare and life-threatening genetic diseases.
-
A.
CRISPR Therapeutics
CRISPR Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat serious diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
D.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
E.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
Created at: April 17, 2026, 3:30 p.m.